Drug regulators are questioning whether an experimental drug for rheumatoid arthritis has too great of a cancer risk and whether it actually works as well as the drug company claims. The drug, tofacitinib, marketed by Pfizer, is under review by a Food and Drug Administration (FDA) advisory panel, which will vote whether to recommend the treatment for FDA approval. The FDA isn’t required to follow the advice of its expert panels, but it usually does. Analysts have pegged tofacitinib as a potential blockbuster medication. “Blockbuster drugs” are ones that generate at least $1 billion in revenue for their owner over ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.